The stock of VolitionRX Ltd (AMEX: VNRX) has decreased by -8.28 when compared to last closing price of 0.67.Despite this, the company has seen a loss of -7.58% in its stock price over the last five trading days. prnewswire.com reported 2024-05-29 that HENDERSON, Nevada, May 29, 2024 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced today that Cameron Reynolds, President and Group Chief Executive Officer, will present and be available for one-to-one meetings at the Jefferies Global Healthcare Conference in New York City. Presentation Details: Date: Wednesday, June 5, 2024 Time: 3.30 pm ET (Track 3) Cameron Reynolds, President and Group CEO of Volition, said: “We are dedicated to improving outcomes for people and animals with life-altering diseases such as sepsis and cancer through earlier detection, disease and treatment monitoring.
Is It Worth Investing in VolitionRX Ltd (AMEX: VNRX) Right Now?
Company’s 36-month beta value is 1.15.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VNRX is 61.21M, and currently, short sellers hold a 0.84% ratio of that floaft. The average trading volume of VNRX on June 27, 2024 was 189.62K shares.
VNRX’s Market Performance
VNRX stock saw a decrease of -7.58% in the past week, with a monthly decline of -16.16% and a quarterly a decrease of -18.64%. The volatility ratio for the week is 8.14%, and the volatility levels for the last 30 days are 7.94% for VolitionRX Ltd (VNRX). The simple moving average for the past 20 days is -11.62% for VNRX’s stock, with a -26.79% simple moving average for the past 200 days.
Analysts’ Opinion of VNRX
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VNRX reach a price target of $7, previously predicting the price at $8. The rating they have provided for VNRX stocks is “Overweight” according to the report published on February 17th, 2022.
Cantor Fitzgerald gave a rating of “Overweight” to VNRX, setting the target price at $8 in the report published on March 10th of the previous year.
VNRX Trading at -17.34% from the 50-Day Moving Average
After a stumble in the market that brought VNRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.65% of loss for the given period.
Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 8.14%, as shares sank -10.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.14% lower at present.
During the last 5 trading sessions, VNRX fell by -7.58%, which changed the moving average for the period of 200-days by -52.34% in comparison to the 20-day moving average, which settled at $0.6867. In addition, VolitionRX Ltd saw -14.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VNRX starting from Eight Corp Ltd, who sale 20,000 shares at the price of $0.90 back on Jan 02 ’24. After this action, Eight Corp Ltd now owns 298,419 shares of VolitionRX Ltd, valued at $18,000 using the latest closing price.
Butera Salvatore Thomas, the CEO – Volition Veterinary of VolitionRX Ltd, purchase 10,000 shares at $0.83 during a trade that took place back on Dec 18 ’23, which means that Butera Salvatore Thomas is holding 99,350 shares at $8,300 based on the most recent closing price.
Stock Fundamentals for VNRX
Current profitability levels for the company are sitting at:
- -44.32 for the present operating margin
- -0.76 for the gross margin
The net margin for VolitionRX Ltd stands at -43.8. The total capital return value is set at 2.93. Equity return is now at value -5396.85, with -186.28 for asset returns.
Based on VolitionRX Ltd (VNRX), the company’s capital structure generated -0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -3.72. The debt to equity ratio resting at -0.31. The interest coverage ratio of the stock is -142.72.
Currently, EBITDA for the company is -34.58 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 55.65. The receivables turnover for the company is 5.97for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.43.
Conclusion
In a nutshell, VolitionRX Ltd (VNRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
